

Press release

BRAIN Biotech AG and Biocatalysts Ltd Launch a New Initiative to Revolutionize Enzyme Solutions within the Life Science Industry

Zwingenberg, Germany and Cardiff, United Kingdom, October 1, 2024 - BRAIN Biotech Zwingenberg and Biocatalysts Ltd have aligned core competencies to revolutionize the enzyme development within the Life Science market by addressing the significant challenges with IP restrictions and scale up. The launch of the *BRAIN-Biocatalysts Life Science Solutions* initiative combines BRAIN Biotech's cutting-edge enzyme discovery and optimization expertise with Biocatalysts' world-class commercial-scale manufacturing, delivering an unparalleled, end-to-end solution for the life sciences sector. By offering end-to-end services, from enzyme discovery to large-scale manufacturing, this bold venture is set to disrupt the market by offering a transparent IP strategy that guarantees partners full control over their innovations.

The collaboration is powered by BRAIN Biotech AG's unique enzyme discovery platform MetXtra™, combining bioinformatics, AI, and novel enzyme sequences. This comes alongside Biocatalysts' state-of-the-art fermentation facility in Cardiff, UK housing fermentation capacities of up to 10,000L and comprehensive downstream processing capabilities. The collaboration is further enhanced by the proprietary "Plug & Produce" platform of microbial fermentation strains for immediate large-scale production, allowing partners to engage at any stage of development.

To spearhead this initiative, *BRAIN-Biocatalysts Life Science Solutions* has assembled a team of world-class experts, with decades of experience in enzyme solutions for molecular diagnostics and DNA modification alongside delivering biocatalytic solutions to the pharmaceutical industry for over 20 years.

"With *BRAIN-Biocatalysts Life Science Solutions* we are the first in the market to offer a truly end-to-end enzyme development and production platform in the small molecule API, DNA modification and molecular diagnostics markets." said Adriaan Moelker, CEO of BRAIN Biotech AG. "This collaboration not only fills a critical gap, but also empowers partners with seamless enzyme development solutions from discovery to large-scale manufacturing, ensuring they can innovate without barriers".

About BRAIN Biotech

BRAIN Biotech AG is a leading provider of integrated solutions and products in the field of industrial biotechnology. The company specializes in enzymes and proteins, microbial production strains and bioprocesses for biotechnological production methods. BRAIN Biotech focuses on the growth markets of nutrition and life sciences as well as on innovative solutions for environment issues. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. Its business activities are divided into three segments: 1. BioProducts: Production and sale of specialty enzymes and proteins; 2. BioScience: Customized solutions based on enzyme engineering, production strain and bioprocess development, and screening for bioactive compounds; 3. BioIncubator: Pipeline of research-intensive development projects. For production, the Group operates fermentation plants in the UK and other production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 310 people and generated revenues of EUR 55.3 million in the fiscal year 2022/23. For more information, please visit www.brain-biotech-group.com

About Biocatalysts Ltd.

Biocatalysts Ltd, established in 1983, Biocatalysts has been a member of the international BRAIN Biotech Group since 2018. Biocatalysts is an industry expert in the discovery, development, and manufacture of speciality enzymes. The team of specialists boast an extensive knowledge of enzymes, from their application, development, cloning and production to process optimisation and the creation of new products. The four sites house specialist capabilities from a state-of-the-art fermentation facility to an expert application & bakery excellence centre to a highly advanced refrigerated liquid blending site. Coupled with the industrial biotechnology prowess of the BRAIN Biotech Group they usher in a #biobasedfuture. Together, they assembled a state-of-the art biotechnology toolkit, that combines tools and flexibility to craft customized solutions.

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.